Table 2. Antibody mediated neutralisation of different influenza virus subtypes.
| Clone | X-1811(H1N1) IC50 nM2 | NIBRG-141 (H5N1)IC50 nM | NIBRG-1471 (H2N2)IC50 nM | NIBRG-911 (H9N2)IC50 nM | NIBRG-1091 (H7N2)IC50 nM |
| R1a-G5 | 14.2±3.1 | − 4 | ND5 | ND | ND |
| R2b-D8 | - | - | ND | ND | ND |
| R2b-E8 | 40.0±11.4 | 14.9±4.9 | - | - | - |
| R2b-D9 | 40.7±11.8 | 14.9±4.7 | 134.3±67.2 | - | - |
| R1a-F4 | +3 | - | ND | ND | ND |
| R1a-A5 | 11.9±1.3 | 4.0±2.0 | - | - | - |
| R1a-C5 | 20.2±2.7 | - | - | - | - |
| R1a-E5 | 125.7±7.6 | - | ND | ND | ND |
| R1a-F5 | - | - | ND | ND | ND |
| R1a-B6 | 3.2±0.5 | 5.5±0.9 | - | 182.2±25.2 | - |
| R1a-E6 | - | - | ND | ND | ND |
| R1a-G6 | 7.3±1.1 | - | ND | ND | ND |
| R2a-E8 | 15.0±5.7 | - | ND | ND | ND |
| R2a-G8 | 212.2 ±18.7 | >1000 | - | - | - |
| R2a-B9 | 26.3±8.2 | - | ND | ND | ND |
| R2a-F9 | 23.2±6.4 | - | ND | ND | ND |
| R2a-G9 | 17.0±4.2 | - | - | ND | - |
| R2a-H9 | 9.9±2.6 | - | ND | ND | ND |
| control | - | - | - | - | - |
Neutralisation of laboratory adapted X-181 strain corresponding to A/California/07/2009 (H1N1)pdm09, NIBRG-14 a reverse genetics reassortant of A/Vietnam/1194/2004 (H5N1) with the polybasic cleavage site removed from the HA, NIBRG-147 reverse genetics reassortant of A/Singapore/01/57 (H2N2), NIBRG-91 reverse genetics reassortant of A/chicken/Hong Kong/G9/97 (H9N2), NIBRG-109 reverse genetics reassortant of A/New York/107/2003 (H7N7).
IC50 is given in nM and is the concentration required to give 50% maximum neutralisation. Data is given as the mean mean of a minimum of three independent assays ± SEM.
+ indicates neutralisation was seen but a IC50 could not be calculated as a maximum level of neutralisation activity was not reached. 4– indicates no neutralisation. 5 ND is not determined.